Russia has effectively been working on its coronavirus vaccine for the past six years, according to the head of the country’s sovereign wealth fund, with a rollout expected before the end of the year.
On Tuesday, Russia announced that it had registered a coronavirus vaccine, making it the first country to do so. There are doubts over its efficacy and safety, however, given that it is still to go through larger-scale Phase 3 clinical trials, and that no data has been published from earlier clinical trials carried out in less than two months.
Russia said its work in recent years on developing a vaccine for Ebola and Middle East Respiratory Syndrome (MERS) had helped it to create a vaccine against the new coronavirus, a virus that emerged in China in late 2019 and one that has now infected more than 20 million people worldwide, causing over 740,000 deaths.
“We were just fortunate that the coronavirus was very close to MERS, so we pretty much had a ready-to-go vaccine on MERS, studied for two years on MERS (and) slightly modified to be the coronavirus vaccine, and that is the real story, no politics … Russia has always been at the forefront of vaccine research,” Kirill Dmitriev, CEO of Russia’s sovereign wealth fund RDIF, which is backing the vaccine, told CNBC.
Russia says vaccine could be in use by November and has been developed over six years, CNBC, Aug 13
- Nasdaq 100 reversed from strong support level 21000.00 - Likely to rise to resistance…
- USDJPY reversed from key support level 156.35 - Likely to rise to resistance level…
The recent declines in US indices may have broken the bullish trend, indicated by technical…
The dollar has paused its strengthening, as weaker-than-expected inflation data reduces fear of future Fed…
Bitcoin finds support near the 50-day moving average, but further declines in the stock market…
- EURCHF falling inside minor impulse wave 5 - Likely to fall to support level…
This website uses cookies